Provided by Tiger Fintech (Singapore) Pte. Ltd.

Elevation Oncology, Inc.

0.3720
-0.0061-1.61%
Post-market: 0.37800.0060+1.61%19:35 EDT
Volume:1.25M
Turnover:473.52K
Market Cap:22.03M
PE:-0.48
High:0.3959
Open:0.3825
Low:0.3600
Close:0.3781
Loading ...

Analysts’ Top Healthcare Picks: Opus Genetics (IRD), Elevation Oncology (ELEV)

TIPRANKS
·
15 Dec 2024

Elevation Oncology Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Dec 2024

BRIEF-Synaffix Elevation Oncology Licenses ADC Technology From Synaffix To Drive Pipeline Expansion

Reuters
·
12 Dec 2024

BRIEF-Elevation Oncology Expands Pipeline With Nomination Of EO-1022

Reuters
·
12 Dec 2024

Synaffix: Elevation Oncology Licenses ADC Technology From Synaffix to Drive Pipeline Expansion

THOMSON REUTERS
·
12 Dec 2024

Synaffix: Co Is Eligible to Receive up to $368 Mln in Upfront and Clinical, Regulatory, and Commercial Milestone Payments

THOMSON REUTERS
·
12 Dec 2024

Elevation Oncology nominates EO-1022 as its HER3 ADC development candidate

TIPRANKS
·
12 Dec 2024

Elevation Oncology enters licensing agreement with Synaffix B.V.

TIPRANKS
·
12 Dec 2024

Elevation Oncology Expands Pipeline With Nomination of Eo-1022, a Her3 ADC for the Treatment of Her3-Expressing Solid Tumors

THOMSON REUTERS
·
12 Dec 2024

Elevation Oncology Inc: Expects to Present Eo-1022 Preclinical Data in 1H 2025 and to File an Ind Application in 2026

THOMSON REUTERS
·
12 Dec 2024

Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors

PR Newswire
·
12 Dec 2024

Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion

PR Newswire
·
12 Dec 2024

Elevation Oncology Price Target Maintained With a $5.00/Share by Stephens & Co.

Dow Jones
·
07 Dec 2024

Elevation Oncology presents positive Phase 1 results of EO-3021 combination

TIPRANKS
·
05 Dec 2024

Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024

PR Newswire
·
05 Dec 2024

Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference

PR Newswire
·
26 Nov 2024

Elevation Oncology’s Promising Progress and Potential: Buy Rating Justified by Advancements in Gastric Cancer Treatment and Strong Financial Outlook

TIPRANKS
·
07 Nov 2024

TD Cowen Sticks to Its Buy Rating for Elevation Oncology (ELEV)

TIPRANKS
·
07 Nov 2024

Elevation Oncology reports Q3 EPS (22c), consensus (20c)

TIPRANKS
·
06 Nov 2024

Elevation Oncology-Sees Existing Cash, Cash Equivalents,Marketable Securities as of Sept 30 to Be Sufficient to Fund Current Operations Into 2026

THOMSON REUTERS
·
06 Nov 2024